SBP GROUP (01177.HK) -0.060 (-1.136%) Short selling $40.76M; Ratio 19.291% announced that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of the Company, entered into an exclusive strategic collaboration with GlaxoSmithKline (GSK) to accelerate bepirovirsen in mainland China at launch.Under the agreement, CTTQ will be responsible for importation, distribution, hospital access, and promotional and non-promotional activities for bepirovirsen in mainland China. Revenue generated from product sales in China is expected to be recognised by CTTQ. GSK will remain the marketing authorisation holder (MAH) and retain responsibility for regulatory, quality, pharmacovigilance and global medical strategy. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)
AASTOCKS Financial News